Zobrazeno 1 - 10
of 51
pro vyhledávání: ''
Autor:
Yansong Liu, Xinzhao Wang, Chao Li, Xiaoli Bian, Zhaoyun Liu, Xiang Song, Wei Zhao, Zhiyong Yu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 23, Pp 8352-8364 (2021)
Cancer Medicine, Vol 10, Iss 23, Pp 8352-8364 (2021)
The previous studies had demonstrated the promising effectiveness and acceptable safety of pyrotinib in patients with HER2‐positive metastatic breast cancer. We aimed to investigate the real‐world data of pyrotinib in complex clinical practice an
Autor:
Hung T. Khong, Christine Laronga, Hatem Soliman, Aixa E. Soyano‐Muller, Hyo S. Han, Junjie Ma, Xiaojun Zhong, Susan J. Hoover, Brian J. Czerniecki, John V. Kiluk, Loretta Loftus, Ricardo Costa, Avan Armaghani, Nazanin Khakpour, M. Catherine Lee, James Sun, Weihong Sun
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7665-7672 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7665-7672 (2021)
Background Combination CDK4/6 inhibitor and endocrine therapy has been shown to significantly improve progression‐free survival (PFS) in patients with hormone receptor (HR)‐positive, HER2‐negative metastatic breast cancer (mBC). The aim of this
Autor:
Caitlin C. Murphy, Danyi Xiong, Bhumika Maddineni, Ethan A. Halm, David E. Gerber, Sandi L. Pruitt, Hong Zhu, Daniel F. Heitjan, Anna Tavakkoli, Amit G. Singal
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4752-4767 (2021)
Cancer Medicine, Vol 10, Iss 14, Pp 4752-4767 (2021)
Patients with previous cancer are often excluded from clinical trials despite limited evidence about their prognosis. We examined the effect of previous cancer on overall and colorectal cancer (CRC)‐specific survival of patients newly diagnosed wit
Autor:
Menglu Zhang, Meng Zhou, Changchang Wang, Xiang Wang, Jie Wang, Hongxia Gao, Hengqiang Zhao, Zeyu Xing, Tianyi Qian, Hongyan Chen, Jiaqi Liu, Siqi Bao, Xiangzhi Meng, Xin Wang, Yalun Li
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 15, Iss 9, Pp 2466-2479 (2021)
Molecular Oncology, Vol 15, Iss 9, Pp 2466-2479 (2021)
Sentinel lymph node (LN) biopsy is currently the standard procedure for clinical LN‐negative breast cancer (BC) patients but it is prone to false‐negative results and complications. Thus, an accurate noninvasive approach for LN staging is urgentl
Autor:
Brent J. Small, Andrew J. Saykin, Jeanne S. Mandelblatt, Heather S.L. Jim, Deena Graham, Brenna C. McDonald, Judith E. Carroll, James C. Root, Asma A. Dilawari, Tim A. Ahles, Zev M. Nakamura, Harvey J. Cohen, Kelly E. Rentscher, Kathleen Van Dyk, Sunita K. Patel, Jaeil Ahn, Wanting Zhai, Xingtao Zhou, Traci N. Bethea
Publikováno v:
Cancer
Background The coronavirus disease 2019 (COVID‐19) pandemic has had wide‐ranging health effects and increased isolation. Older with cancer patients might be especially vulnerable to loneliness and poor mental health during the pandemic. Methods T
Autor:
Zhihui Liu, Michael A. Herman, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Geoffrey Liu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4814-4822 (2021)
Cancer Medicine, Vol 10, Iss 14, Pp 4814-4822 (2021)
Objectives Approximately 20% of patients diagnosed with non‐small cell lung cancer (NSCLC) have a history of prior (non‐lung) cancer. Patients with prior cancer are frequently excluded from clinical trials. We aimed to assess the potential impact
Autor:
Manjunath Nookala, Vikram Gota, Ashwin Karanam, Anand P. Patil, Navin Goyal, Ashish Singh, Murari Gurjar, Avinash Bonda, Yogesh Kembhavi, Sudeep Gupta, Bharati Shriyan
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 9, Pp 3068-3076 (2021)
Cancer Medicine, Vol 10, Iss 9, Pp 3068-3076 (2021)
Background Paclitaxel is dosed according to body surface area (BSA) but there is scant information on actual drug exposure in overweight and obese patients. Methods Early breast cancer patients receiving paclitaxel at 175 mg/m2 every 3 weeks, in two
Autor:
Yasuto Naoi, Seung Jin Kim, Masafumi Shimoda, Tomonori Tanei, Yoshiaki Sota, Yasufumi Sato, Shinzaburo Noguchi, Naofumi Kagara, Kenzo Shimazu, Tomohiro Miyake
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 4, Pp 1418-1430 (2021)
Cancer Medicine, Vol 10, Iss 4, Pp 1418-1430 (2021)
Humoral immunity plays a substantial role in the suppression of breast cancer. We have revealed that a high serum concentration of anti‐HER2 autoantibody (HER2‐AAb) is associated with favorable outcomes in patients with invasive breast cancer. Th
Autor:
Stephen Leong, S.G. Eckhardt, Jodi A. Kagihara, Virginia F. Borges, Jennifer A Weiss, Dexiang Gao, Andrew Nicklawsky, Jennifer R. Diamond, Anthony D. Elias, Peter Kabos, Christine M. Fisher, Sarah Lindsey Davis
Publikováno v:
Cancer Medicine
Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trial
Autor:
Yannan Zhao, Yizhao Xie, Yi Li, Biyun Wang, Chengcheng Gong, Jun Cao, Zhonghua Tao, Leiping Wang, Xichun Hu, Jian Zhang
Publikováno v:
Cancer Medicine
Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine t